{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:39:21Z","timestamp":1758814761343},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00415-008-3004-y","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T07:16:24Z","timestamp":1218006984000},"page":"12-16","source":"Crossref","is-referenced-by-count":13,"title":["IVIg in other autoimmune neurological disorders: current status and future prospects"],"prefix":"10.1007","volume":"255","author":[{"given":"Marinos","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,7]]},"reference":[{"key":"3004_CR1","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"Basta","year":"1994","unstructured":"Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94:1729\u20131735","journal-title":"J Clin Invest"},{"key":"3004_CR2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","volume":"58","author":"Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58:326","journal-title":"Neurology"},{"key":"3004_CR3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"Dalakas","year":"2001","unstructured":"Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immune globulin for stiffperson syndrome. N Engl J Med 345:1870\u20131876","journal-title":"N Engl J Med"},{"key":"3004_CR4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"3004_CR5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712\u2013716","journal-title":"Neurology"},{"key":"3004_CR6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Dauvilliers","year":"2004","unstructured":"Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905\u2013908","journal-title":"Ann Neurol"},{"key":"3004_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"Dodel","year":"2002","unstructured":"Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B, Moller HJ, Farlow M, Oertel WH, Sommer N, Du Y (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer\u2019s disease. Ann Neurol 52:253\u2013256","journal-title":"Ann Neurol"},{"key":"3004_CR8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"Dodel","year":"2004","unstructured":"Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against betaamyloid for the treatment of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 75:1472\u20131474","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3004_CR9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","volume":"126","author":"Du","year":"2003","unstructured":"Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M (2003) Human antibeta-amyloid antibodies block betaamyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126:1935\u20131939","journal-title":"Brain"},{"key":"3004_CR10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41:789\u2013796","journal-title":"Ann Neurol"},{"key":"3004_CR11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"Gajdos","year":"2005","unstructured":"Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 62:1689\u20131693","journal-title":"Arch Neurol"},{"key":"3004_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-3-1","volume":"3","author":"Goebel","year":"2003","unstructured":"Goebel A, Moore A, Weatherall R, Roewer N, Schedel R, Sprotte G (2003) Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: a study protocol [ISRCTN33042138]. BMC Neurol 3:1","journal-title":"BMC Neurol"},{"key":"3004_CR13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ana.20400","volume":"57","author":"Goebel","year":"2005","unstructured":"Goebel A, Stock M, Deacon R, Sprotte G, Vincent A (2005) Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol 57:463\u2013464","journal-title":"Ann Neurol"},{"key":"3004_CR14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jneuroim.2005.01.018","volume":"162","author":"Goebel","year":"2005","unstructured":"Goebel A, Vogel H, Caneris O, Bajwa Z, Clover L, Roewer N, Schedel R, Karch H, Sprotte G, Vincent A (2005) Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. J Neuroimmunol 162:184\u2013189","journal-title":"J Neuroimmunol"},{"key":"3004_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-510X(02)00316-7","volume":"205","author":"Gonzalez","year":"2002","unstructured":"Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T (2002) Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 205:9\u201313","journal-title":"J Neurol Sci"},{"key":"3004_CR16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","volume":"5","author":"Gonzalez","year":"2006","unstructured":"Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5:493\u2013500","journal-title":"Lancet Neurol"},{"key":"3004_CR17","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"Raju","year":"2005","unstructured":"Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:1887\u20131896","journal-title":"Brain"},{"key":"3004_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2006.04.011","volume":"176","author":"Zhu","year":"2006","unstructured":"Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S (2006) Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol 176:187\u2013197","journal-title":"J Neuroimmunol"},{"key":"3004_CR19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837\u2013841","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-008-3004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-008-3004-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-008-3004-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:08:18Z","timestamp":1559056098000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-008-3004-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":19,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["3004"],"URL":"https:\/\/doi.org\/10.1007\/s00415-008-3004-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}